 |
1 Product |  |
1 Disease | | 1 Product |
|
0 Trials |  |
10 News |  |
- || dexamethasone / Generic mfg., Decadron (dexamethasone) / Merck (MSD), DSP-Visulex (dexamethasone sodium phosphate ophthalmic) / Aciont
Clinical, P1/2 data, Journal: Novel Dexamethasone Sodium Phosphate Treatment (DSP-Visulex) for Non-Infectious Anterior Uveitis: A Randomized Phase I/II Clinical Trial. (Pubmed Central) - Apr 16, 2020
The efficacy of the DSP-Visulex applications was comparable to the daily PA drops in the treatment of non-infectious anterior uveitis. Both 8% and 15% DSP-Visulex treatments were safe and well tolerated.
- | DSP-Visulex (dexamethasone sodium phosphate ophthalmic) / Aciont
Clinical, Journal: Ocular Drug Distribution and Safety of a Noninvasive Ocular Drug Delivery System of Dexamethasone Sodium Phosphate in Rabbit. (Pubmed Central) - Oct 4, 2019
Repeat applications of DSP-Visulex are safe and well tolerated for weekly administrations over 4-12 weeks. DSP-Visulex has clinical potential for the noninvasive treatment of ocular diseases.
- | DSP-Visulex (dexamethasone sodium phosphate ophthalmic) / Aciont
Trial completion, Trial primary completion date: Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis (clinicaltrials.gov) - Apr 27, 2017
P1/2, N=44, Completed, Sponsor: Aciont Inc
DSP-Visulex has clinical potential for the noninvasive treatment of ocular diseases. Recruiting --> Completed | Trial primary completion date: Nov 2016 --> Mar 2017
- DSP-Visulex (dexamethasone sodium phosphate ophthalmic) / Aciont
Trial primary completion date: Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis (clinicaltrials.gov) - Jul 19, 2016
P1/2, N=45, Recruiting, Sponsor: Aciont Inc
Recruiting --> Completed | Trial primary completion date: Nov 2016 --> Mar 2017 Trial primary completion date: Dec 2015 --> Nov 2016
- DSP-Visulex (dexamethasone sodium phosphate ophthalmic) / Aciont
New P1/2 trial: Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis (clinicaltrials.gov) - Dec 5, 2014
P1/2, N=45, Recruiting, Sponsor: Aciont Inc